1. Randomized, controlled, open-label, non-inferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa 
F. Olivennes, G. Trew, A. Borini, F. Broekmans, P. Arriagada, D.W. Warne, C.M. Howles 
Reproductive BioMedicine Online 
Volume 30, Issue 3, Pages (March 2015)
DOI: /j.rbmo
Copyright © 2014 Reproductive Healthcare Ltd. Terms and Conditions

2. Figure 1
Patient disposition. Disposition is presented for all patients up to randomization and, thereafter, for the modified intention-to-treat population.
aOne patient in each treatment group received recombinant HCG but was subsequently discontinued from the study for lack of ovarian response to ovarian stimulation and were excluded from the modified intention-to-treat-population.
GnRH = gonadotrophin-releasing hormone; OHSS = ovarian hyperstimulation syndrome; rHCG = recombinant HCG; rFSH = recombinant human FSH.
Reproductive BioMedicine Online  , DOI: ( /j.rbmo )
Copyright © 2014 Reproductive Healthcare Ltd. Terms and Conditions

3. Figure 2
The estimated difference (95% confidence interval) in the mean number of oocytes retrieved between the CONSORT and standard-dosing groups (modified ITT population).The study tested non-inferiority in terms of number of oocytes retrieved in the CONSORT group versus standard dosing. The null hypothesis was that the difference in mean number of oocytes retrieved (CONSORT minus standard-dosing group) was −3 or less; the alternate hypothesis was that the difference was greater than −3. ITT = intent to treat.
Reproductive BioMedicine Online  , DOI: ( /j.rbmo )
Copyright © 2014 Reproductive Healthcare Ltd. Terms and Conditions